We are excited to announce that Haystack Oncology will be participating in the American Society for Clinical Oncology (ASCO) annual meeting in Chicago, Illinois June 2-6.
The ASCO annual meeting is a gathering of one of the largest and most diverse groups of oncology professionals, with more than 40,000 attendees involved in the study, diagnosis, and treatment of people with cancer.
Haystack MRD™ is a tumor-informed ctDNA detection test to monitor for residual and recurrent disease after curative intent surgery. The test is powered by Haystack Duo™ sequencing chemistry, which significantly reduces noise to detect even the least-abundant ctDNA molecules in blood. This unique ability translates to better minimal residual disease (MRD) detection for greater confidence when making key clinical decisions.
If you plan on attending, we invite you to stop by our booth #28111 to learn more about the clinical utility of our ultra-sensitive, tumor-informed MRD assay. Hope to see you there!
